The strong volume growth supports the commercial narrative for CyPath Lung in a pre-earnings window. Monitor the Q2 2026 financial results expected in August for actual revenue dollar amounts and path to profitability. No financial data in this filing — the bullish signal is from volume metrics only.
Price Chart
Executive Summary
bioAffinity Technologies filed an 8-K announcing that Q2 2026 CyPath Lung test sales volume more than doubled year-over-year (over 200% growth) and grew over 30% sequentially from Q1 2026. This is a purely operational update with no financial data — the company expects to report Q2 2026 financial results in August. For a $4M market cap commercial-stage diagnostics company, the strong volume growth is a positive signal for the commercial launch trajectory.
Key Facts
- CyPath Lung test sales volume for Q2 2026 grew more than 200% year-over-year
- Sequential growth of more than 30% over Q1 2026
- Physician offices ordering CyPath Lung increased 155% vs Q2 2025
- Nearly 3,000 CyPath Lung tests performed since commercial launch
- Revenue and financial results to be reported in August 2026 — not disclosed in this filing
- Market cap is approximately $4M
Financial Impact
No dollar revenue figures disclosed. The volume growth metrics (200% YoY, 30% QoQ) suggest strong commercial adoption, but absolute revenue base remains unknown and likely small given the $4M market cap.
Risk Factors
- No financial data disclosed — absolute revenue levels remain unknown for a $4M market cap company
- Forward-looking statements about expansion and physician adoption are not guaranteed
- Regulatory environment for Laboratory Developed Tests (LDTs) carries uncertainty
- Company expects to report Q2 financials in August — actual revenue numbers could disappoint relative to volume growth claims
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-032263 |
| Exhibit: ex99-1.htm | 0001493152-26-032263 |
| Document: 0001493152-26-032263-index-headers.html | 0001493152-26-032263 |
| Document: 0001493152-26-032263-index.html | 0001493152-26-032263 |
| Document: 0001493152-26-032263.txt | 0001493152-26-032263 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEF 14A | $2.81 | awaiting T+1 | — | $2.83 (+0.71%) |
Oct 15, 2026 11d ago | 8-K | $3.96 $3.73 | ▼ −5.81% | ▼ −4.70% | $2.83 (−28.54%) |
Oct 13, 2026 13d ago | 8-K | $3.63 $3.56 | ▼ −1.79% | ▼ −0.71% | $2.83 (−21.93%) |
Oct 9, 2026 17d ago | 8-K | $3.90 $3.63 | ▲ +7.05% | ▲ +7.04% | $2.83 (+27.44%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▲ +17.46% | ▲ +17.40% | $2.83 (+40.11%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▼ −17.46% | ▼ −17.40% | $2.83 (−40.11%) |
Oct 8, 2026 18d ago | 8-K | $5.64 $4.73 | ▼ −16.22% | ▼ −16.82% | $2.83 (−49.82%) |
Oct 6, 2026 20d ago | 8-K | $6.06 $6.16 | ▲ +1.65% | ▲ +1.89% | $2.83 (−53.30%) |
Sep 30, 2026 26d ago | 8-K | $6.56 $6.15 | ▼ −6.33% | ▼ −6.50% | $2.83 (−56.86%) |
Sep 22, 2026 4w ago | 8-K | $8.56 $7.94 | ▼ −7.19% | ▼ −6.47% | $2.83 (−66.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers